About PAMPRx

PAMPRx is developing a first-in-class, host-directed immunotherapy platform that targets pathogen-associated molecular patterns (PAMPs)—molecular signatures found in the cell walls of bacteria and viruses that chronically activate the human immune system.

PAMPs are structural fragments shed by microbes (such as peptidoglycan, lipoteichoic acid, and lipopolysaccharide) that are recognized by innate immune receptors like Toll-like receptors (TLRs) and NOD-like receptors (NODs). While critical for mounting an immune response during infection, persistent exposure to PAMPs—particularly from gut, skin, and oral microbiota—can drive chronic low-grade inflammation associated with numerous diseases.

The PAMPRx platform uses extended half-life monoclonal antibodies to neutralize the most immunostimulatory bacterial PAMPs—lipoteichoic acid (LTA) and peptidoglycan (PGN)—before they can trigger systemic immune activation via TLR2 and NOD1/2. These receptors, unlike TLR4, lack negative feedback controls, making their activation a non-resolving source of inflammation in conditions ranging from metabolic dysfunction to neurodegeneration.

What makes PAMPRx unique is that it modulates immune activation without suppressing the immune system itself. Unlike steroids, JAK inhibitors, or cytokine blockers, PAMPRx preserves host defense while resolving inflammation at its upstream microbial root.

The platform has also identified viral PAMPs as expansion targets, and is protected by filed IP covering both current and future antigen targets.

PAMPRx’s clinical strategy focuses on rapid, biomarker-driven validation using procalcitonin (PCT) and C-reactive protein (CRP) as pharmacodynamic endpoints—both of which are well-established markers of innate immune activation. If early-phase trials demonstrate reductions in these markers, the likelihood of success across multiple chronic inflammatory diseases is significantly elevated.